Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Name: Kaimen Rigor review — Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Item: Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Rating: 94
Author: Alpha1

Cho BC, Balaraman R, Chen HJ, Yu X, Fawole A, Liu ZG, Zhang J, Wu L, Yang B, Leddon JL, Hamm J, Huang Y, Wu L, Pan P, Singh P, Beardsley A, Kayali F, Davarifar A, Lee KH, Park KU, Lee Y, Li L, Wang X, Sun M, Yu Y, Jain V, Shpyro S, Wang Q, Wenger M, Şahin U, Efuni S, Song S, He K, Zheng P, Liu Y, He K, Li T, Socinski MA, Wu YL

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04323-8

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/86573dda-4c72-4851-9bca-34ae3ffbe9b6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/86573dda-4c72-4851-9bca-34ae3ffbe9b6/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

070846097f20f0b0f88ecc3c20eee364fd353090f7d94bfe546c324f3401ac2b

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Paper source

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Biggest issues

01Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Stage 1 results suggest that gotistobart may offer a chemotherapy-free treatment option to transform the treatment paradigm of sqNSCLC.
“the results from the nonpivotal stage 1 of this phase 3 randomized study suggest that gotistobart may offer a chemotherapy-free treatment option to transform the treatment paradigm of sqNSCLC with better outcomes for patients.”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong and unusually transparent report of an open-label, randomized phase 3 (stage 1, exploratory) trial: ethics, registration, randomization, limitations, negative results, and funding/COI are all thoroughly reported, and the 3 recomputable statistics are consistent. The main weaknesses are that the proportional-hazards assumption is not addressed, the data-availability statement names no access platform/committee (and no code-sharing), and the headline 'transform the treatment paradigm' conclusion is overstated relative to a non-powered 87-patient exploratory stage.

Statistics verification was partial: only 3 tests were machine-recomputable and all were consistent; exact and threshold-only p-values, the log-rank p, and resampling-based tests were not machine-verifiable and should not be treated as confirmed. Citations: 35 checked, 0 retracted, 0 not-found (no integrity flags). The reviewers agreed on 7 of 8 dimensions and split on data code availability; both positions are preserved in that dimension's evidence.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

2 findings · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Prior work is cited extensively, including the modest efficacy of docetaxel and the unmet need. The rationale for gotistobart's mechanism of action is explained. However, the paper does not explicitly describe how limitations of prior research (e.g., failed trials) are addressed, though the study design implicitly addresses them.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study establishes a clear scientific foundation: it documents the unmet need in PD-(L)1/chemotherapy-resistant sqNSCLC, the modest efficacy of the docetaxel standard of care, and the mechanism-based rationale for gotistobart from prior work.

Evidence

paraphrase[Introduction, paragraph 2]

“Docetaxel has modest efficacy, as patients with PD-(L)1-resistant sqNSCLC have a median survival ranging from 8.0 to 9.4 months, and treatment is associated with considerable toxicity.”

paraphrase[Introduction, paragraph 4]

“In the first-in-human phase 1/2 PRESERVE-001 study in patients with advanced solid tumors in different tumor indications, gotistobart at doses of up to 10 mg kg−1 administered once every 3 weeks (Q3W) was clinically active with a manageable safety profile.”

“the median OS reported with docetaxel in our study is relatively higher than the upper end of the range reported by other studies in a second-line sqNSCLC population (8.0 to 9.4 months)”

Discussion ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior work on the poor prognosis of sqNSCLC, the modest efficacy of docetaxel, and preclinical/phase 1 data on gotistobart, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1]

“Docetaxel has modest efficacy, as patients with PD-(L)1-resistant sqNSCLC have a median survival ranging from 8.0 to 9.4 months, and treatment is associated with considerable toxicity.”

paraphrase[Introduction, paragraph 2]

“Gotistobart (BNT316/ONC-392) is a novel tumor microenvironment-selective regulatory T cell (Treg) depletion antibody targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4).”

absence[Introduction, paragraphs 1-3]

Limitations of prior research are not explicitly addressed as a sub-criterion.

Randomization used an Interactive Web Response System. The study is open-label (stated but no rationale). Stage 1 was exploratory and not powered, which is acknowledged. Inclusion/exclusion criteria are detailed. Outlier handling is implicit via ITT and safety populations. Blinding, randomization unit, and other criteria are adequately reported.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

The core design elements are adequately reported for a human RCT: IWRS randomization with pre-specified stratification, detailed eligibility criteria, an explicitly stated open-label design with acknowledged limitations, and a defined analysis population.

Evidence

“Eligible patients were randomized using the Interactive Web Response System to receive gotistobart or docetaxel treatment stratified by factors that could impact prognosis: histology (squamous versus nonsquamous (stage 1 only)), presence of brain metastases (yes or no), ECOG PS score (0 versus 1) and region (USA and ex-USA).”

MethodsFind in source

“randomized, open-label, active-controlled phase 3 trial”

DiscussionFind in source

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

ResultsFind in source

PASSReviewer 2· 90% conf

The study design is adequately described for a clinical trial, with randomization method, inclusion/exclusion criteria, and analysis populations reported. The open-label design is stated but without a rationale, and the power analysis is appropriately noted as not applicable for this exploratory stage.

Evidence

paraphrase[Methods, Randomization and stratification factors]

“Eligible patients were randomized using the Interactive Web Response System to receive gotistobart or docetaxel treatment stratified by factors...”

paraphrase[Methods, Study design and patients]

“...randomized, open-label, active-controlled phase 3 trial...”

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

Results ¶1Find in source

Sex is reported (Table 1: 80% male in gotistobart, 90.5% in docetaxel). Age is reported (median 64 vs 68.5 years). Health status (ECOG PS) is reported. Demographics include race, region, smoking status. Weight is not reported, but this is not a standard requirement for clinical trials.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Sex, age, health status (ECOG PS), and extensive demographics are reported in the baseline table; sex-justification is not applicable since both sexes were enrolled.

Evidence

“Median age (range) in years | 64.0 (39–86) | 68.5 (43–84) | | Sex, no. (%) | Male | 36 (80.0) | 38 (90.5)”

Table 1Find in source

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

DiscussionFind in source

PASSReviewer 2· 90% conf

Biological variables (sex, age, health status, demographics) are reported in Table 1, meeting the criteria for a human clinical trial.

Evidence

“Sex, no. (%) | Male | 36 (80.0) | 38 (90.5) | | Female | 9 (20.0) | 4 (9.5)”

Table 1Find in source

“ECOG PS score, no. (%) | 0 | 9 (20.0) | 7 (16.7) | | 1 | 36 (80.0) | 35 (83.3)”

Table 1Find in source

“Race, no. (%) | Asian | 32 (71.1) | 30 (71.4) | | White | 11 (24.4) | 11 (26.2)”

Table 1Find in source

The paper includes a dedicated ethics section stating approval by the Western Institutional Review Board and local ethics committees. Written informed consent was obtained. Compliance with regulations is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Ethical compliance is fully reported: named IRB approval (Western IRB in the USA, site ethics committees elsewhere), written informed consent, and adherence to the Declaration of Helsinki and ICH-GCP.

Evidence

“The central Western Institutional Review Board provided approval in the USA.”

EthicsFind in source

“All patients provided written informed consent before enrollment.”

EthicsFind in source

“The study was conducted in accordance with local and national regulations, as well as consensus ethical principles derived from the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines and the International Council for Harmonisation Good Clinical Practice Guidelines.”

EthicsFind in source

PASSReviewer 2· 100% conf

Ethical approvals and consent are comprehensively reported, including a named IRB, written informed consent, and compliance with Declaration of Helsinki and ICH-GCP.

Evidence

“The central Western Institutional Review Board provided approval in the USA.”

EthicsFind in source

“All patients provided written informed consent before enrollment.”

EthicsFind in source

paraphrase[Methods, Ethics approval and consent]

“The study was conducted in accordance with ... the Declaration of Helsinki, ... and the International Council for Harmonisation Good Clinical Practice Guidelines.”

Gotistobart is identified by name, source (OncoC4), and dose regimen. Docetaxel is identified by name and dose. SAS version 9.4 is specified. No other resources (antibodies, cell lines, etc.) are applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

The investigational products (gotistobart and docetaxel) are identified with dosing regimens and source, and the analysis software (SAS 9.4) is identified; bench-lab resource criteria are not applicable to this drug trial.

Evidence

paraphrase[Abstract / Methods, Treatments]

“gotistobart (6 mg kg−1 with two 10 mg kg−1 loading doses every 3 weeks (N = 45)) or docetaxel (75 mg m−2 every 3 weeks (N = 42))”

“Statistical analyses were conducted using SAS (version 9.4 or later).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (gotistobart) and comparator (docetaxel) are identified with dose/regimen, and statistical software is identified with version.

Evidence

paraphrase[Methods, Treatments]

“gotistobart was administered at 6 mg kg−1 (with two loading doses of 10 mg kg−1)”

paraphrase[Methods, Treatments]

“Docetaxel was dosed at 75 mg m−2.”

“Statistical analyses were conducted using SAS (version 9.4 or later).”

Statistical analysisFind in source

Ext and effect sizes with CIs are reported. The paper does not mention checking proportional hazards or other assumptions, which is a minor omission. Data presentation includes KM curves and tables with n per group.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical reporting follows the clinical-trial idiom: named tests (Cox model, log-rank, exact binomial), exact p-values, effect estimates with 95% CIs, and identified software; reported percentages and ORR counts are internally consistent.

Evidence

“hazard ratio (HR) 0.46, 95% CI 0.25 to 0.84, two-sided P value = 0.0102”

ResultsFind in source

“HRs and associated 95% CIs were calculated from a Cox proportional-hazards model.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are adequately described for a clinical trial, with exact p-values, effect sizes with CIs, and software identification. Assumptions verification is not explicitly reported, but the design uses standard methods.

Evidence

paraphrase[Results, Primary outcomes]

“HR 0.46, 95% CI 0.25 to 0.84, two-sided P value = 0.0102”

paraphrase[Results, Primary outcomes]

“median OS was not reached (95% CI 9.3 months to NE) with gotistobart and 10.0 months (95% CI 6.2 to 11.9 months) with docetaxel”

absence[Methods, Statistical analysis]

Assumptions verification not mentioned.

The statement says data will be made available to qualified researchers upon request within 12 months, but no concrete platform or committee is specified. This does not meet the standard for adequate reporting.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

A concrete managed-access route for the patient data is described with a named contact, a data-access agreement, a timeframe, and anonymization; patient-level clinical data preclude open repository deposit.

Evidence

“Upon completion of this clinical trial, the data that support the findings of this study will be made available to qualified researchers. Proposals should be directed to pzheng@oncoc4.com.”

Data availabilityFind in source

“To gain access, data requestors will need to sign a data access agreement. All data provided will be anonymized to respect the privacy of patients who have participated in the trial”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement is present but is vague, providing only an email and timeframe without a named platform or data-access committee, which is inadequate for a clinical trial.

Evidence

“Data will be made available; to qualified researchers upon request, within 12 months of the study completion data and for a period of 2 years thereafter.”

Data availabilityFind in source

All applicable sub-criteria are adequately addressed. The paper is written in a transparent manner appropriate for a clinical trial report.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Reporting is complete and transparent: detailed methods, trial registration (NCT05671510), a reporting summary, transparent negative results (non-sqNSCLC and low-dose arm), a limitations section, proportional conclusions, and full funding/COI disclosures.

Evidence

“PRESERVE-003 (ClinicalTrials.gov registration: NCT05671510 (https://clinicaltrials.gov/ct2/show/NCT05671510) ; date of registration: 4 January 2023)”

MethodsFind in source

“For patients with non‑sqNSCLC, the median OS, 12-month survival rates and median PFS were numerically better in the docetaxel arm than in the gotistobart arm”

ResultsFind in source

“The use of investigator assessment rather than blinded, independent central reviewer assessment of PFS and ORR may be limited by the open-label design.”

DiscussionFind in source

PASSReviewer 2· 95% conf

The manuscript is thorough and transparent, with detailed methods, trial registration, a reporting summary, all outcomes reported, limitations discussed, conclusions proportional to evidence, and funding/COI statements.

Evidence

“ClinicalTrials.gov identifier: NCT05671510”

AbstractFind in source

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

Discussion ¶8Find in source

paraphrase[Acknowledgements and Competing interests]

“The PRESERVE-003 study is sponsored by OncoC4 Inc. and conducted in collaboration with BioNTech.”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 35 references by DOI: 31 verified — 4 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

As a published record, the study is robust and meets clinical-trial reporting standards, but an informed reader should weigh the exploratory, non-powered nature of stage 1 and the open-label, investigator-assessed endpoints when interpreting the OS/HR signal, and should treat the 'transform the treatment paradigm' conclusion as stronger than the evidence supports. A correction or clarification addressing the proportional-hazards assumption, the safety-population n discrepancy (n=41 vs randomized n=42), and tempering the headline claim would strengthen the record; the data-access statement should name a platform/committee to be fully actionable.

1.
HIGHrigor
Publish a correction or clarification in the Discussion replacing the 'transform the treatment paradigm of sqNSCLC' claim with language limited to a promising, exploratory signal, since a non-powered 87-patient stage 1 cannot support a paradigm-shift conclusion.
The claim-audit component rated this headline conclusion as overstated relative to the evidence; over-claiming is the most common and most consequential reviewer/reader objection.
2.
HIGHstatistics
Add a statement to the Statistical analysis section (or a correction note) on whether the proportional-hazards assumption of the Cox model was assessed for OS and PFS; if not assessed, say so and flag it as a limitation.
Both reviewers noted the assumption check is absent, and readers cannot assess the validity of the primary HR without knowing whether PH held.
3.
MEDIUMdata code
Clarify in the Data availability section whether the SAS analysis code and analysis datasets will be shared alongside the patient data, and name a specific managed-access platform (e.g., Vivli, YODA) or data-access committee rather than only an email address.
Reviewer 2 judged the statement vague without a named platform/committee, and Reviewer 1 noted code-sharing is unaddressed; making the route concrete and including code improves reproducibility.
4.
MEDIUMreporting
Add a brief sample-size/power rationale for stage 1 in the Statistical analysis section, even if only to quantify the number of patients needed to characterize the dose and frame the exploratory intent.
Reviewer 1 flagged the absence of any a priori sample-size rationale; the current text only states the stage 'was not powered to demonstrate efficacy'.
5.
MEDIUMreporting
State the rationale for the open-label design in the Methods (Study design) section, and note explicitly in the Discussion's limitations that open-label, investigator-assessed PFS/ORR may introduce bias.
Reviewer 2 noted the open-label design is stated without justification; the limitation is partially acknowledged but the lack of rationale should be disclosed.
6.
MEDIUMcopyedit
Clarify in the Table 3 footnote (or safety text) that one randomized docetaxel patient did not receive treatment, explaining the safety analysis n=41 versus the randomized n=42.
The copyedit pass flagged this n discrepancy as potentially confusing to readers even though it is explained in the text.
7.
MEDIUMcopyedit
Align the abstract safety percentages (42% and 49%) with the body values (42.2% and 48.8%), or state explicitly that they are rounded.
The copyedit pass flagged a consistency ambiguity between the abstract and the body safety results.
8.
LOWcopyedit
Add a clarifying note in the Discussion that the ipilimumab 3 mg/kg dose is a different agent/indication, to avoid confusion with the 3 mg/kg gotistobart arm that was terminated by the DMC.
The copyedit pass flagged that the ipilimumab comparison could be misread as referring to the terminated gotistobart 3 mg/kg arm.
9.
LOWreporting
Add a brief note in Table 1 or the Methods that body weight was not reported, or state that weight is not a required baseline variable for this clinical-trial context.
Reviewer 2 noted weight is not reported; an explicit statement avoids the appearance of an omission.

Full text (59,928 chars)Analyzed: Aug 10, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04323-8

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/86573dda-4c72-4851-9bca-34ae3ffbe9b6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/86573dda-4c72-4851-9bca-34ae3ffbe9b6/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

070846097f20f0b0f88ecc3c20eee364fd353090f7d94bfe546c324f3401ac2b

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Biggest issues

01Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Stage 1 results suggest that gotistobart may offer a chemotherapy-free treatment option to transform the treatment paradigm of sqNSCLC.
“the results from the nonpivotal stage 1 of this phase 3 randomized study suggest that gotistobart may offer a chemotherapy-free treatment option to transform the treatment paradigm of sqNSCLC with better outcomes for patients.”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit3 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

2 findings · worst medium

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

paraphrase[Introduction, paragraph 2]

“Docetaxel has modest efficacy, as patients with PD-(L)1-resistant sqNSCLC have a median survival ranging from 8.0 to 9.4 months, and treatment is associated with considerable toxicity.”

paraphrase[Introduction, paragraph 4]

“the median OS reported with docetaxel in our study is relatively higher than the upper end of the range reported by other studies in a second-line sqNSCLC population (8.0 to 9.4 months)”

Discussion ¶3Find in source

PASSReviewer 2· 90% conf

Evidence

paraphrase[Introduction, paragraph 1]

“Docetaxel has modest efficacy, as patients with PD-(L)1-resistant sqNSCLC have a median survival ranging from 8.0 to 9.4 months, and treatment is associated with considerable toxicity.”

paraphrase[Introduction, paragraph 2]

“Gotistobart (BNT316/ONC-392) is a novel tumor microenvironment-selective regulatory T cell (Treg) depletion antibody targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4).”

absence[Introduction, paragraphs 1-3]

Limitations of prior research are not explicitly addressed as a sub-criterion.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

MethodsFind in source

“randomized, open-label, active-controlled phase 3 trial”

DiscussionFind in source

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

ResultsFind in source

PASSReviewer 2· 90% conf

Evidence

paraphrase[Methods, Randomization and stratification factors]

“Eligible patients were randomized using the Interactive Web Response System to receive gotistobart or docetaxel treatment stratified by factors...”

paraphrase[Methods, Study design and patients]

“...randomized, open-label, active-controlled phase 3 trial...”

“Stage 1 is exploratory and was not powered to demonstrate efficacy.”

Results ¶1Find in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Sex, age, health status (ECOG PS), and extensive demographics are reported in the baseline table; sex-justification is not applicable since both sexes were enrolled.

Evidence

“Median age (range) in years | 64.0 (39–86) | 68.5 (43–84) | | Sex, no. (%) | Male | 36 (80.0) | 38 (90.5)”

Table 1Find in source

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

DiscussionFind in source

PASSReviewer 2· 90% conf

Biological variables (sex, age, health status, demographics) are reported in Table 1, meeting the criteria for a human clinical trial.

Evidence

“Sex, no. (%) | Male | 36 (80.0) | 38 (90.5) | | Female | 9 (20.0) | 4 (9.5)”

Table 1Find in source

“ECOG PS score, no. (%) | 0 | 9 (20.0) | 7 (16.7) | | 1 | 36 (80.0) | 35 (83.3)”

Table 1Find in source

“Race, no. (%) | Asian | 32 (71.1) | 30 (71.4) | | White | 11 (24.4) | 11 (26.2)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

“The central Western Institutional Review Board provided approval in the USA.”

EthicsFind in source

“All patients provided written informed consent before enrollment.”

EthicsFind in source

PASSReviewer 2· 100% conf

Ethical approvals and consent are comprehensively reported, including a named IRB, written informed consent, and compliance with Declaration of Helsinki and ICH-GCP.

Evidence

“The central Western Institutional Review Board provided approval in the USA.”

EthicsFind in source

“All patients provided written informed consent before enrollment.”

EthicsFind in source

paraphrase[Methods, Ethics approval and consent]

“The study was conducted in accordance with ... the Declaration of Helsinki, ... and the International Council for Harmonisation Good Clinical Practice Guidelines.”

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

paraphrase[Abstract / Methods, Treatments]

“gotistobart (6 mg kg−1 with two 10 mg kg−1 loading doses every 3 weeks (N = 45)) or docetaxel (75 mg m−2 every 3 weeks (N = 42))”

“Statistical analyses were conducted using SAS (version 9.4 or later).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (gotistobart) and comparator (docetaxel) are identified with dose/regimen, and statistical software is identified with version.

Evidence

paraphrase[Methods, Treatments]

“gotistobart was administered at 6 mg kg−1 (with two loading doses of 10 mg kg−1)”

paraphrase[Methods, Treatments]

“Docetaxel was dosed at 75 mg m−2.”

“Statistical analyses were conducted using SAS (version 9.4 or later).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

“hazard ratio (HR) 0.46, 95% CI 0.25 to 0.84, two-sided P value = 0.0102”

ResultsFind in source

“HRs and associated 95% CIs were calculated from a Cox proportional-hazards model.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Evidence

paraphrase[Results, Primary outcomes]

“HR 0.46, 95% CI 0.25 to 0.84, two-sided P value = 0.0102”

paraphrase[Results, Primary outcomes]

“median OS was not reached (95% CI 9.3 months to NE) with gotistobart and 10.0 months (95% CI 6.2 to 11.9 months) with docetaxel”

absence[Methods, Statistical analysis]

Assumptions verification not mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

“Upon completion of this clinical trial, the data that support the findings of this study will be made available to qualified researchers. Proposals should be directed to pzheng@oncoc4.com.”

Data availabilityFind in source

“To gain access, data requestors will need to sign a data access agreement. All data provided will be anonymized to respect the privacy of patients who have participated in the trial”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement is present but is vague, providing only an email and timeframe without a named platform or data-access committee, which is inadequate for a clinical trial.

Evidence

“Data will be made available; to qualified researchers upon request, within 12 months of the study completion data and for a period of 2 years thereafter.”

Data availabilityFind in source

All applicable sub-criteria are adequately addressed. The paper is written in a transparent manner appropriate for a clinical trial report.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

“PRESERVE-003 (ClinicalTrials.gov registration: NCT05671510 (https://clinicaltrials.gov/ct2/show/NCT05671510) ; date of registration: 4 January 2023)”

MethodsFind in source

“For patients with non‑sqNSCLC, the median OS, 12-month survival rates and median PFS were numerically better in the docetaxel arm than in the gotistobart arm”

ResultsFind in source

“The use of investigator assessment rather than blinded, independent central reviewer assessment of PFS and ORR may be limited by the open-label design.”

DiscussionFind in source

PASSReviewer 2· 95% conf

Evidence

“ClinicalTrials.gov identifier: NCT05671510”

AbstractFind in source

“A limitation of the study is that the Asian patient population was overrepresented, and Hispanic and Black/African American patients were underrepresented in stage 1.”

Discussion ¶8Find in source

paraphrase[Acknowledgements and Competing interests]

“The PRESERVE-003 study is sponsored by OncoC4 Inc. and conducted in collaboration with BioNTech.”

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 35 references by DOI: 31 verified — 4 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHrigor
Publish a correction or clarification in the Discussion replacing the 'transform the treatment paradigm of sqNSCLC' claim with language limited to a promising, exploratory signal, since a non-powered 87-patient stage 1 cannot support a paradigm-shift conclusion.
The claim-audit component rated this headline conclusion as overstated relative to the evidence; over-claiming is the most common and most consequential reviewer/reader objection.
2.
HIGHstatistics
Add a statement to the Statistical analysis section (or a correction note) on whether the proportional-hazards assumption of the Cox model was assessed for OS and PFS; if not assessed, say so and flag it as a limitation.
Both reviewers noted the assumption check is absent, and readers cannot assess the validity of the primary HR without knowing whether PH held.
3.
MEDIUMdata code
Clarify in the Data availability section whether the SAS analysis code and analysis datasets will be shared alongside the patient data, and name a specific managed-access platform (e.g., Vivli, YODA) or data-access committee rather than only an email address.
Reviewer 2 judged the statement vague without a named platform/committee, and Reviewer 1 noted code-sharing is unaddressed; making the route concrete and including code improves reproducibility.
4.
MEDIUMreporting
Add a brief sample-size/power rationale for stage 1 in the Statistical analysis section, even if only to quantify the number of patients needed to characterize the dose and frame the exploratory intent.
Reviewer 1 flagged the absence of any a priori sample-size rationale; the current text only states the stage 'was not powered to demonstrate efficacy'.
5.
MEDIUMreporting
State the rationale for the open-label design in the Methods (Study design) section, and note explicitly in the Discussion's limitations that open-label, investigator-assessed PFS/ORR may introduce bias.
Reviewer 2 noted the open-label design is stated without justification; the limitation is partially acknowledged but the lack of rationale should be disclosed.
6.
MEDIUMcopyedit
Clarify in the Table 3 footnote (or safety text) that one randomized docetaxel patient did not receive treatment, explaining the safety analysis n=41 versus the randomized n=42.
The copyedit pass flagged this n discrepancy as potentially confusing to readers even though it is explained in the text.
7.
MEDIUMcopyedit
Align the abstract safety percentages (42% and 49%) with the body values (42.2% and 48.8%), or state explicitly that they are rounded.
The copyedit pass flagged a consistency ambiguity between the abstract and the body safety results.
8.
LOWcopyedit
Add a clarifying note in the Discussion that the ipilimumab 3 mg/kg dose is a different agent/indication, to avoid confusion with the 3 mg/kg gotistobart arm that was terminated by the DMC.
The copyedit pass flagged that the ipilimumab comparison could be misread as referring to the terminated gotistobart 3 mg/kg arm.
9.
LOWreporting
Add a brief note in Table 1 or the Methods that body weight was not reported, or state that weight is not a required baseline variable for this clinical-trial context.
Reviewer 2 noted weight is not reported; an explicit statement avoids the appearance of an omission.

Full text (59,928 chars)Analyzed: Aug 10, 2026